Quantcast

Israel-based bladder cancer biotech Anchiano Therapeutics files for a $35 million US IPO


Shutterstock photo

Anchiano Therapeutics, a Phase 3 biotech developing therapies for early-stage bladder cancer, filed on Monday with the SEC to raise up to $35 million in an initial public offering. Insiders intend to purchase up to $17.5 million of the IPO (50% of the deal). 

The Jerusalem, Israel-based company was founded in 2004 and plans to list on the Nasdaq under the symbol ANCN. Anchiano Therapeutics filed confidentially on September 22, 2018. Oppenheimer & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Israel-based bladder cancer biotech Anchiano Therapeutics files for a $35 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.




This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?